Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)
 
 • Company Description   
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Number of Employees: 278

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.89 Daily Weekly Monthly
20 Day Moving Average: 590,424 shares
Shares Outstanding: 56.49 (millions)
Market Capitalization: $558.68 (millions)
Beta: 0.59
52 Week High: $21.86
52 Week Low: $9.24
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.76% 2.76%
12 Week -22.31% -14.58%
Year To Date -36.97% -22.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2200 PENNSYLVANIA AVE NW SUITE 300E
-
WASHINGTON,DC 20037
USA
ph: 202-734-3400
fax: 202-296-1450
pr@vandapharma.com http://www.vandapharma.com
 
 • General Corporate Information   
Officers
Mihael H. Polymeropoulos - President; Chief Executive Officer and Chairman
Kevin Moran - Chief Financial Officer
H. Thomas Watkins - Lead Independent Director
Anne Sempowski Ward - Director
Phaedra Chrousos - Director

Peer Information
Vanda Pharmaceuticals Inc. (CORR.)
Vanda Pharmaceuticals Inc. (RSPI)
Vanda Pharmaceuticals Inc. (CGXP)
Vanda Pharmaceuticals Inc. (BGEN)
Vanda Pharmaceuticals Inc. (GTBP)
Vanda Pharmaceuticals Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 921659108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 56.49
Most Recent Split Date: (:1)
Beta: 0.59
Market Capitalization: $558.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.30 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 32.97
Trailing 12 Months: 30.91
PEG Ratio: -
Price Ratios
Price/Book: 1.11
Price/Cash Flow: 14.64
Price / Sales: 2.10
EPS Growth
vs. Year Ago Period: -173.33%
vs. Previous Quarter: -191.67%
Sales Growth
vs. Year Ago Period: -3.95%
vs. Previous Quarter: -11.51%
ROE
03/31/22 - 3.65
12/31/21 - 6.81
09/30/21 - 7.23
ROA
03/31/22 - 3.08
12/31/21 - 5.80
09/30/21 - 6.16
Current Ratio
03/31/22 - 5.42
12/31/21 - 6.43
09/30/21 - 6.41
Quick Ratio
03/31/22 - 5.41
12/31/21 - 6.41
09/30/21 - 6.40
Operating Margin
03/31/22 - 6.79
12/31/21 - 12.34
09/30/21 - 12.77
Net Margin
03/31/22 - 6.79
12/31/21 - 12.34
09/30/21 - 12.77
Pre-Tax Margin
03/31/22 - 9.16
12/31/21 - 15.77
09/30/21 - 16.65
Book Value
03/31/22 - 8.89
12/31/21 - 9.06
09/30/21 - 8.85
Inventory Turnover
03/31/22 - 23.66
12/31/21 - 23.60
09/30/21 - 22.45
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©